|
|
(8 intermediate revisions by the same user not shown) |
Line 1: |
Line 1: |
| {{ Poster }} | | {{ Poster }} |
| | | |
− | <html><head> | + | <html><head></head><body> |
| + | |
| + | |
| + | |
| <!-- <link rel="stylesheet" href="../css/styles.css"> --> | | <!-- <link rel="stylesheet" href="../css/styles.css"> --> |
| <style> | | <style> |
Line 126: |
Line 129: |
| /* FONTS END */ | | /* FONTS END */ |
| </style> | | </style> |
− | </head> | + | |
− | <body> | + | |
| <div class="page_wrapper"> | | <div class="page_wrapper"> |
| <div class="poster_w content"> | | <div class="poster_w content"> |
Line 191: |
Line 194: |
| <b>45.6% to 60.9%</b>, reaching <b>84.3%</b> when caused by | | <b>45.6% to 60.9%</b>, reaching <b>84.3%</b> when caused by |
| <b>XDR <i>A. baumannii</i></b>. <br/><br/> | | <b>XDR <i>A. baumannii</i></b>. <br/><br/> |
− | As a In our solution, we use pyocins, which are high molecular | + | As a solution, we use pyocins, which are high molecular |
| weight bactericidal protein complexes produced by | | weight bactericidal protein complexes produced by |
| <i>P. aeruginosa</i>. Pyocins attach to receptors on the | | <i>P. aeruginosa</i>. Pyocins attach to receptors on the |
Line 212: |
Line 215: |
| <div class="text"> | | <div class="text"> |
| <h3>Inspiration</h3> | | <h3>Inspiration</h3> |
− | Interviews with doctors and ICU specialists made us realise it | + | Interviews with doctors and ICU specialists made us realise |
− | clear the necessity for alternative treatments for drug | + | the necessity for alternative treatments for drug |
| resistant infections in the face of rapid AMR development. | | resistant infections in the face of rapid AMR development. |
| <br/><br/> | | <br/><br/> |
Line 314: |
Line 317: |
| | | |
| As a chassis we chose to produce them in | | As a chassis we chose to produce them in |
− | <i>Escherichia coli</i>, specifically strain BL21(DE3).As an | + | <i>Escherichia coli</i>, strain BL21(DE3).As an |
| expression vector, we chose pET-28 a from Novagen which contains | | expression vector, we chose pET-28 a from Novagen which contains |
− | a T7 promoter and lac operator, allowing | + | a T7 promoter and <i>lac operator</i>, allowing |
− | IPTG-controllableinduced protein expression. | + | IPTG-induced protein expression. |
| | | |
| <br/><br/> | | <br/><br/> |
Line 409: |
Line 412: |
| | | |
| We have introduced two new basic Parts to the iGEM registry as a | | We have introduced two new basic Parts to the iGEM registry as a |
− | contribution for us ebay future iGEM teams. | + | contribution for us future iGEM teams. |
| | | |
| <br/> | | <br/> |
Line 462: |
Line 465: |
| <li class="wiki-li"> | | <li class="wiki-li"> |
| The team received insightful facts on the situation of | | The team received insightful facts on the situation of |
− | AMR infections inside ICUs during CoVID-19. | + | AMR infections inside ICUs during COVID-19. |
| </li> | | </li> |
| <li class="wiki-li"> | | <li class="wiki-li"> |
| We got to know that doctors use IL-6 antagonists and | | We got to know that doctors use IL-6 antagonists and |
− | immunosuppressants for CoVID Regulation. | + | immunosuppressants for COVID Regulation. |
| </li> | | </li> |
| <li class="wiki-li"> | | <li class="wiki-li"> |
Line 780: |
Line 783: |
| | | |
| <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/d/db/T--IIT_Roorkee--Poster_images--poster-content--poster_implementation_1.jpg"/> | | <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/d/db/T--IIT_Roorkee--Poster_images--poster-content--poster_implementation_1.jpg"/> |
− | </div>
| + | <div class=""> |
− | <div class="">
| + | Surfactant consists of 80-85 % phospholipids, 5-10 % neutral |
− | Surfactant consists of 80-85 % phospholipids, 5-10 % neutral
| + | lipids, and 8-10 % protein, with 5-6 % of the four specific |
− | lipids, and 8-10 % protein, with 5-6 % of the four specific
| + | proteins of surfactant. Broadly, the formulation has the |
− | proteins of surfactant. Broadly, the formulation has the
| + | following structure: |
− | following structure:
| + | |
− | </div>
| + | |
− | <br/><br/>
| + | |
− | <div class="">
| + | |
− | <div class="table-responsive">
| + | |
− | <table class="table table-hover table-bordered">
| + | |
− | <thead class="thead-dark">
| + | |
− | <tr>
| + | |
− | <th scope="col">
| + | |
− | <b>Mucolytics:</b> Carbocisteine, Erdosteine.
| + | |
− | </th>
| + | |
− | <th scope="col">
| + | |
− | <b>Bronchodilators:</b>Beta-2 agonists,
| + | |
− | Anticholinergics, Theophylline
| + | |
− | </th>
| + | |
− | </tr>
| + | |
− | </thead>
| + | |
− | <tbody>
| + | |
− | <tr>
| + | |
− | <td>Seekercin A</td>
| + | |
− | <td>di-Palmitoylphosphatidylcholine (DPPC)</td>
| + | |
− | </tr>
| + | |
− | <tr>
| + | |
− | <td>Seekercin B</td>
| + | |
− | <td>Phosphatidylglycerol</td>
| + | |
− | </tr>
| + | |
− | <tr>
| + | |
− | <td>Seekercin C</td>
| + | |
− | <td>Phosphatidylinositol</td>
| + | |
− | </tr>
| + | |
− | </tbody>
| + | |
− | </table>
| + | |
| </div> | | </div> |
− | </div>
| |
− | <br/><br/>
| |
− | <div class="">
| |
− | By instilling a particular microvolume of liquid into the upper
| |
− | airways and moving the plug by programmed air ventilation into
| |
− | the desired region of the lung, the aqueous liquid containing
| |
− | soluble drugs can be delivered into targeted branches of the
| |
− | lung airway and deposited onto the lung epithelium .
| |
− | </div>
| |
− | <br/><br/>
| |
− | <div class="">
| |
− | <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/8/84/T--IIT_Roorkee--Poster_images--poster-content--poster_implementation_2.jpg"/>
| |
− | </div>
| |
− | <br/><br/>
| |
− | <div class="">
| |
− | We researched and decided on delivery of pyocins through
| |
− | nebulizers however, in India there is a disproportionately large
| |
− | problem with VAPs in the Newborn Intensive Care Units.
| |
− | <br/>
| |
− | (NICU) (60k+ deaths per year).
| |
| <br/><br/> | | <br/><br/> |
− | On seeking an expert opinion from a Doctor (NICU/VAP | + | <div class=""> |
− | specialist), he pointed out that neonates, especially preterm,
| + | <div class="table-responsive"> |
− | have underdeveloped lungs that are too delicate for effective
| + | <table class="table table-hover table-bordered"> |
− | nebulizer based treatment. | + | <thead class="thead-dark"> |
| + | <tr> |
| + | <th scope="col"> |
| + | <b>Mucolytics:</b> Carbocisteine, Erdosteine. |
| + | </th> |
| + | <th scope="col"> |
| + | <b>Bronchodilators:</b>Beta-2 agonists, |
| + | Anticholinergics, Theophylline |
| + | </th> |
| + | </tr> |
| + | </thead> |
| + | <tbody> |
| + | <tr> |
| + | <td>Seekercin A</td> |
| + | <td>di-Palmitoylphosphatidylcholine (DPPC)</td> |
| + | </tr> |
| + | <tr> |
| + | <td>Seekercin B</td> |
| + | <td>Phosphatidylglycerol</td> |
| + | </tr> |
| + | <tr> |
| + | <td>Seekercin C</td> |
| + | <td>Phosphatidylinositol</td> |
| + | </tr> |
| + | </tbody> |
| + | </table> |
| + | </div> |
| + | </div> |
| <br/><br/> | | <br/><br/> |
− | A big drawback of nebulizer therapy is its poor efficiency of | + | <div class=""> |
− | delivery, much of the dose is lost in the ETT (mist deposition
| + | By instilling a particular microvolume of liquid into the upper |
− | on the walls, medicine does not get misty well, etc.). Drug loss
| + | airways and moving the plug by programmed air ventilation into |
− | is no longer a concern when administering the bolus dose, since
| + | the desired region of the lung, the aqueous liquid containing |
− | the substance itself is injected into the lungs, taking the drug
| + | soluble drugs can be delivered into targeted branches of the |
− | with it. | + | lung airway and deposited onto the lung epithelium . |
| + | </div> |
| <br/><br/> | | <br/><br/> |
− | As observed in in-vivo studies, our rapid and efficient delivery | + | <div class=""> |
− | of bolus-injected surfactant solutions containing
| + | <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/8/84/T--IIT_Roorkee--Poster_images--poster-content--poster_implementation_2.jpg"/> |
− | surfactant-associated proteins such as SP-A to the alveoli shows
| + | </div> |
− | a strong precedent for delivery of Seekercin is also more likely
| + | |
− | to ensure the delivery of high doses (10 ^ 12 pyocins per ml)
| + | |
− | needed for successful treatment. The dose will easily enter the
| + | |
− | alveoli, and it is predicted that changes will be observed | + | |
− | within seconds to minutes.
| + | |
| <br/><br/> | | <br/><br/> |
| + | <div class=""> |
| + | We researched and decided on delivery of pyocins through |
| + | nebulizers however, in India there is a disproportionately large |
| + | problem with VAPs in the Newborn Intensive Care Units. |
| + | <br/> |
| + | (NICU) (60k+ deaths per year). |
| + | <br/><br/> |
| + | On seeking an expert opinion from a Doctor (NICU/VAP |
| + | specialist), he pointed out that neonates, especially preterm, |
| + | have underdeveloped lungs that are too delicate for effective |
| + | nebulizer based treatment. |
| + | <br/><br/> |
| + | A big drawback of nebulizer therapy is its poor efficiency of |
| + | delivery, much of the dose is lost in the ETT (mist deposition |
| + | on the walls, medicine does not get misty well, etc.). Drug loss |
| + | is no longer a concern when administering the bolus dose, since |
| + | the substance itself is injected into the lungs, taking the drug |
| + | with it. |
| + | <br/><br/> |
| + | As observed in in-vivo studies, our rapid and efficient delivery |
| + | of bolus-injected surfactant solutions containing |
| + | surfactant-associated proteins such as SP-A to the alveoli shows |
| + | a strong precedent for delivery of Seekercin is also more likely |
| + | to ensure the delivery of high doses (10 ^ 12 pyocins per ml) |
| + | needed for successful treatment. The dose will easily enter the |
| + | alveoli, and it is predicted that changes will be observed |
| + | within seconds to minutes. |
| + | <br/><br/> |
| + | </div> |
| </div> | | </div> |
| </div> | | </div> |
Line 928: |
Line 931: |
| <div class="text"> | | <div class="text"> |
| <h3 class="wiki-h wiki-h3">Wet Lab</h3> | | <h3 class="wiki-h wiki-h3">Wet Lab</h3> |
− | <br/><br/> | + | <br/> |
| Initial experiments were performed in March but had to be | | Initial experiments were performed in March but had to be |
| aborted due to the pandemic and closing of our institute. We | | aborted due to the pandemic and closing of our institute. We |
| have laid out contingency plans for multiple scenarios based on | | have laid out contingency plans for multiple scenarios based on |
| the expected results of our wet lab experiments. | | the expected results of our wet lab experiments. |
− | <br/><br/> | + | <br/><br/><br/> |
| <h3 class="wiki-h wiki-h3">Dry Lab</h3> | | <h3 class="wiki-h wiki-h3">Dry Lab</h3> |
− | <br/><br/> | + | <br/> |
| <div class="flex-row"> | | <div class="flex-row"> |
| <div class="img-third"> | | <div class="img-third"> |
Line 973: |
Line 976: |
| </div> | | </div> |
| </div> | | </div> |
− | <br/><br/>
| |
− | <br/>
| |
| <br/><br/> | | <br/><br/> |
| <div class="table-responsive"> | | <div class="table-responsive"> |
Line 1,180: |
Line 1,181: |
| <p id="section_text"></p> | | <p id="section_text"></p> |
| </div> | | </div> |
− | </div>
| |
− |
| |
− | <div style="text-align: center;">
| |
| </div> | | </div> |
| | | |
| | | |
| </body></html> | | </body></html> |